Načítá se...

尼洛替尼一线治疗慢性髓性白血病的疗效及影响实现分子学反应的因素分析

OBJECTIVE: This study aimed to investigate the efficacy and safety of nilotinib as the first-line treatment for patients with chronic myelogenous leukemia (CML) and analyze the factors affecting the realization of the major molecular response. METHODS: A retrospective study was conducted on 86 newly...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Zhonghua Xue Ye Xue Za Zhi
Médium: Artigo
Jazyk:Inglês
Vydáno: Editorial office of Chinese Journal of Hematology 2020
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7378290/
https://ncbi.nlm.nih.gov/pubmed/32654460
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.06.007
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!